Author Correction: Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial (Nature Medicine, (2023), 29, 6, (1437-1447), 10.1038/s41591-023-02326-3)
: Mummery C.J., Börjesson-Hanson A., Blackburn D.J., Vijverberg E.G.B., De Deyn P.P., Ducharme S., Jonsson M., Schneider A., Rinne J.O., Ludolph A.C., Bodenschatz R., Kordasiewicz H., Swayze E.E., Fitzsimmons B., Mignon L., Moore K.M., Yun C., Baumann T., Li D., Norris D.A., Crean R., Graham D.L., Huang E., Ratti E., Bennett C.F., Junge C., Lane R.M.
Publisher: Nature Research
: 2024
Nature Medicine
: Nature Medicine
: 304
: 30
: 1078-8956
: 1546-170X
DOI: https://doi.org/10.1038/s41591-023-02639-3
: https://www.nature.com/articles/s41591-023-02639-3
: https://research.utu.fi/converis/portal/detail/Publication/181983815
